EQL Pharma AB (publ) (STO:EQL)

Q1 21/22

← View all transcripts

Aug 17, 2021

We are fully integrated for the method of the product. So we very effective set up, going to have a deal. We on mute, Christopher. We have a factor exclusivity at FRATEALTO and deal tenders. Februca, although for your DOMAX, it will dollars be till OpEx for the second OpenOdetta. Sometimes, we are leveraging our indirect affairs model and OCHE and product development platform. Yes, okay.

• Quarterly report